Funding

Research in the laboratory is supported by the National Institutes of Health, by disease foundations, and by institutional programs at Brown University and, previously, Brigham and Women’s Hospital.

We are particularly indebted to the foundation and pilot awards. Much of the work described on the research pages began with a small grant that funded an observation well before it was developed enough to compete for federal support, and several of those observations became the basis of later career development and R01 awards. Trainees have also brought their own fellowship support to the laboratory.

Current support

MYC as a driver of hypoxia-induced pulmonary hypertension

2026–2028 · Innovation Research Award · Pulmonary Hypertension Association

Role of lactate transporters in pulmonary fibrosis

2023–2028 · R01 HL167718 · National Heart, Lung, and Blood Institute

Past support

Development of small molecule therapeutics for reperfusion injury

2024–2025 · Ignite Seed Grant · Brigham and Women's Hospital

Quantifying metabolic reprogramming in pulmonary hypertension in vivo

2022–2025 · Innovation Evergreen Fund · Brigham Research Institute

Role of lactate transporters in pulmonary fibrosis

2022–2023 · Fund to Sustain Research Excellence · Brigham Research Institute

Therapeutic potential of lactate transport inhibition in pulmonary arterial hypertension

2021–2022 · Fund to Sustain Research Excellence · Brigham Research Institute

Taurine metabolism in the pathobiology of pulmonary hypertension

2018–2020 · Cardiovascular Research and Medical Education Fund

Regulation of pulmonary vascular cell redox state by L-2-hydroxyglutarate

2016–2021 · K08 HL128802 · National Heart, Lung, and Blood Institute

Metabolic flux analysis in pulmonary arterial hypertension

2016–2018 · RG-415134 · American Lung Association

Metabolic flux analysis in pulmonary arterial hypertension

2016–2018 · Pulmonary Hypertension Association and American Thoracic Society Foundation

As co-investigator

Endothelial proline utilization in pulmonary arterial hypertension

2024–2025 · R03 HL172985 · National Heart, Lung, and Blood Institute · PI: Bradley Wertheim

Lipid-mediated control of acetyl-CoA metabolism in the pathogenesis of NAFLD

2024–2025 · R01 DK048873 · National Institute of Diabetes and Digestive and Kidney Diseases · PI: David Cohen

Branched-chain keto-acids and aerobic glycolysis in vascular smooth muscle cells

2023–2025 · R01 HL166137 · National Heart, Lung, and Blood Institute · PI: Joseph Loscalzo

Immunometabolic pathways enabled by PARP inhibition in breast cancer

2022–2025 · R37 CA269499 · National Cancer Institute · PI: Jennifer Guerriero

Cancer reticulotyping consortium

2021–2025 · Northpond Laboratories · PI: Joseph Loscalzo

A collaborative research network to discover immunological therapies for cardiac arrest

2021–2023 · Transformational Project Award · American Heart Association · PI: Edy Kim

Network medicine, risk stratification, and pulmonary hypertension

2019–2021 · R21 HL145420 · National Heart, Lung, and Blood Institute · PI: Bradley Maron

mTOR drives post-sepsis immunosuppression

2019–2020 · American Thoracic Society Foundation · PI: Edy Kim

Held by lab members

The effect of the endothelial glycocalyx on superoxide dismutase, glutathione peroxidase, and nitric oxide synthase activities

2020–2024 · Sarah McGarrity · Postdoctoral Fellowship for Research Abroad · Novo Nordisk Foundation

No matching items